GC Green Cross Wellbeing Holds CEO-Led Corporate Briefing

Sanghyun Kim, CEO of GC Green Cross Wellbeing, is speaking at the corporate briefing held on the 30th of last month at Park One Tower, Yeouido, Yeongdeungpo-gu, Seoul. Photo by GC Green Cross Wellbeing

GC Green Cross Wellbeing announced on June 4 that it held a corporate briefing for institutional investors and analysts at Park One Tower, Yeouido, Yeongdeungpo-gu, Seoul, on May 30.

This corporate briefing was organized following the recent physical spin-off of the health functional food business division. It served as a platform to present the company’s current initiatives for future growth engines. In particular, Sanghyun Kim, CEO of GC Green Cross Wellbeing, personally led the event, strengthening communication with investors and expressing a strong commitment to enhancing corporate value.

During the briefing, the company unveiled its business strategies, including plans to strengthen its position in the non-reimbursed prescription nutritional injection business centered on Laennec, as well as the execution roadmap for the medical aesthetics business, which is being pursued as a future growth engine.

First, as part of its strategy to reinforce the non-reimbursed nutritional injection segment, the company outlined its plans to obtain final approval for the domestic Phase 3 clinical trial of Laennec IV and to expand exports by intensifying marketing efforts following its entry into Hainan Province, China. The company also shared updates on the current status of real world data related to its plan to enter mainland China, reaffirming its commitment to expanding across the entire Chinese market.

Additionally, the execution roadmap for the medical aesthetics business included strategies for overseas market entry for fillers and botulinum toxin products. In particular, following the investment in Inibio, the company plans to expand overseas distribution of botulinum toxin and internalize products such as fillers and skin boosters to enhance its own competitiveness. The overseas export strategy roadmaps for both the non-reimbursed prescription nutritional injection business and the medical aesthetics business attracted significant attention from investors.

Sanghyun Kim, CEO of GC Green Cross Wellbeing, stated, "As a leading company in nutritional injections, GC Green Cross Wellbeing continues to lead the domestic market. While we are a latecomer in aesthetics, we are rapidly expanding our domestic market share through our existing network and will establish ourselves as a new major player in the global aesthetics market in the future."

Meanwhile, in the first quarter, GC Green Cross Wellbeing recorded an operating profit of 5 billion KRW, an increase of 81.6% compared to the same period last year.